Vertex Pharmaceuticals
VRTX
611 hedge funds and large institutions have $36.1B invested in Vertex Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 80 funds opening new positions, 270 increasing their positions, 181 reducing their positions, and 41 closing their positions.
95% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 41
63% more funds holding in top 10
Funds holding in top 10: 8 → 13 (+5)
49% more repeat investments, than reductions
Existing positions increased: 270 | Existing positions reduced: 181
19% more capital invested
Capital invested by funds: $30.4B → $36.1B (+$5.7B)
16% more call options, than puts
Call options by funds: $386M | Put options by funds: $331M
5% more funds holding
Funds holding: 582 → 611 (+29)
0.5% less ownership
Funds ownership: 94.8% → 94.3% (-0.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$285M |
| 2 |
Renaissance Technologies
New York
|
+$203M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$162M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$158M |
| 5 |
Jennison Associates
New York
|
+$145M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$580M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$391M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$289M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$147M |
| 5 |
ClearBridge Investments
New York
|
-$126M |
VRTX Hedge Fund Activity: Q3 2017 in Review
611 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2017, worth a combined $36.1B — up 19% from $30.4B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new VRTX positions and 41 closed out — a net gain of 39 holders — while 270 added to existing stakes and 181 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $285M. The largest seller was Capital World Investors, cutting an estimated $580M.
- 611 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2017, up from 582 in Q2 2017.
- Funds reported $36.1B of Vertex Pharmaceuticals stock for Q3 2017, up 19% quarter-over-quarter.
- 80 funds opened new Vertex Pharmaceuticals positions in Q3 2017 and 41 closed out, a net change of +39 holders.
- The largest Vertex Pharmaceuticals buyer in Q3 2017 was T. Rowe Price Associates, an estimated $285M added.
- The largest Vertex Pharmaceuticals seller in Q3 2017 was Capital World Investors, an estimated $580M sold.
Based on aggregated 13F filings for Q3 2017.